Jo Robson

Rheumatology doctor and researcher with an interest in patient reported outcomes and impact of rare rheumatic diseases- Vasculitis and SLE

[Jo Robson @Robsonjo4]

New! funded PhD opportunity to explore Impact of Steroids on children and young people @CHCR_UWE @ndosie @evemdsmith_eve and Dr Clare Pain #SteroidPRO #quali #proms

[Dr. John Cush @RheumNow]

Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

Sponsored by Amgen

https://t.co/N6C0mxJ7Td

[Vasculitis_Lund @Vasculitis_Lund]

Important publication on Treatment of Giant Cell Arteritis (GCA).
"In patients with GCA, upadacitinib at a dose of 15 mg with a 26-week GCs taper showed efficacy superior to that of PBO with a 52-week GC taper.
https://t.co/cOFKW2ep5C

[Vasculitis - In memory of John Mills MBE 💙💚 @vascuk]

March is #AutoimmuneAwarenessMonth, a time to shine a light on #vasculitis & other autoimmune diseases
Share this post to spread awareness of symptoms for vasculitis, a rare #rheumatic autoimmune disease with over 18 different types, each type extremely rare in its own right!

[vasculitides @vasculitides]

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network
https://t.co/6KJNt8URpJ

[ANZ Vasculitis Society, '26 Vasculitis Wkshop host @anzvasc]

Come join us for #IVW2026 in Australia, and in the vibrant city of Melbourne! February offers perfect summer weather - ideal for beach trips and exploring the city’s famous laneways. Join the Mailing List (https://t.co/h9nW5qpkfw) to keep up to date!

[Association of Women in Rheumatology @AWIRGROUP]

Clinical trial diversity is not optional—it’s critical.

As Dr. Gail Kerr, AWIR’s Director of Clinical Research, emphasizes: “Diversity in clinical trials is essential to understanding how various treatment approaches work in patients from different gene pools, backgrounds, and environments. When research subjects don’t reflect the populations a treatment is designed for, it undermines the quality of care for both patients and physicians, and threatens our ability to practice high-quality medicine.”

The ripple effects of this extend beyond underrepresentation into:
1️⃣ Limited understanding of disease subtype and variations.
2️⃣ Inappropriate treatment and management strategies.
3️⃣ Suboptimal care for vulnerable populations.
4️⃣ Increasing disparities and mistrust among underserved communities.

AWIR is committed to advancing equity through research that addresses these gaps and improves outcomes for all patients. Learn how we’re tackling these challenges: https://t.co/koDf3uAy0y

#DiversityInResearch #ClinicalTrialsMatter #HealthEquity #AWIRLeadership

[ZoiAn @ZoiAn2]

One small step towards the right direction. Thank you!

[OMERACT @OMERACT]

📢 Join us for our Monthly Town Hall featuring the new PRISMA-COSMIN Guideline for reporting systematic reviews of Outcome Measurement Instruments (OMIs)!

🗓️ Dec 17, 2024, 8 AM EST
🔹 With experts Ellen Elsman & Martin Offringa.
Review the guideline & video: https://t.co/ZJtpC9YfwN
🔗 Zoom link: https://t.co/1SdqocF6He

#OMERACT #SystematicReviews #PRISMACOSMINOMI

[Lupus Europe @LupusEurope]

😃Yes! This month's theme is adherence!

💎Adherence is one of the cornerstones of🔝 #lupus management, which requires a comprehensive & multifaceted approach to address the diverse aspects of the disease.

💪A significant part of the journey to #KickLupus lies within our grasp

[ZoiAn @ZoiAn2]

A brilliant opportunity to learn and then share awareness of rare rheumatic diseases.
Thank you for the opportunity to make people with RAIRDs more visible and drive the improvement of care
@RAIRDA_org @LukePollard @UKParliament #vasculitis #rarediseases

[RAIRDA @RAIRDA_org]

Many thanks Jim - this debate will be a brilliant opportunity to raise awareness of the need for improved care and treatment for RAIRDs @LUPUSUK @WeAreSRUK @vascuk @ZoiAn2 @FarrSue01
@SjogrensUK

[UWE Health Research @CHCR_UWE]

We're excited to be starting new research with @BNSSG_ICB @BristolUni @geshNHS to evaluate @getubetter, a self-management app.

Part of a £7.8m investment by @NIHRresearch: https://t.co/FltkHNEgK8

Congratulations to project lead @Alicebez123!

Details: https://t.co/lUNF1h7d1e

[Dr Alice Berry @Alicebez123]

Highlighting inequities across MSK pathways - Supporting People With Musculoskeletal Conditions From Underserved Communities in the United Kingdom to Engage With Physical Activity: A Realist Synthesis and Q-Methodology Study https://t.co/ls0p6mFKGe

[Rheuma Doc @LastManStand85]

Management of #Behcets

The 2024 British Society for #Rheumatology & Dermatology ‘living guideline for managing people with Behcets’. Great Job!

#MedTwitter

[Getting It Right First Time (GIRFT) @NHSGIRFT]

We’re raising awareness of the devastating condition HLH with our new consensus pathway & guidance, out now
EVERYONE needs to see this ▶️https://t.co/Hjr8hFbzEB
Thanks to @RheumatologyUK & @HistioUK for collaboration
1/2
@lanyon_peter @GenQ5Lesley @R_tattersall @JessicaJManson

[Dr Caroline Flurey @C_Flurey]

I wrote a book..! Out now 👇

[RAIRDA @RAIRDA_org]

RAIRDs are a range of conditions in which the body’s immune system damages its own tissues. These conditions include vasculitis, lupus, scleroderma, and Sjögren’s syndrome. RAIRDs can be life-threatening and significantly life-altering. #RAIRDaware #AutoimmuneDiseases #Health

[Pankti Mehta @PanktiMehta24]

Facial rashes that look like lupus but are not ! 🧵🦋

1. Rosacea 🥵
🔹Look for telangiectasia
🔹Involvement of the nasolabial folds 🔹Flushing with spicy foods, heat, & sun exposure

#MedTwitter #RheumTwitter

[The Journal of Rheumatology @jrheum]

Editorial

Health Equity: A Challenging Outcome Measure in Rheumatic Global Health

📖 https://t.co/3SG06YSJTF

#healthequity #indigenous #rheumatoidarthritis

[Alice @AliceEmeliaJ]

Delighted to have attended the conference today and been offered the chance to present my poster 😊🎉